Dual target dilemma: navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma.

Authors	James A Davis, Katelynn Granger, Alex Sakowski, Sara Goodwin, Amanda Herbst, Deidra Smith, Lindsey Hendrickson, Victoria R Nachar
Journal	Expert review of hematology (Expert Rev Hematol) 2023 Jul-Dec Vol. 16 Issue 12 Pg. 915-918 ISSN: 1747-4094 [Electronic] England
PMID	37982732 (Publication Type: Editorial)
Chemical References	glofitamab Antineoplastic Agents Antibodies, Bispecific
Topics	Humans Antineoplastic Agents (therapeutic use) Lymphoma, Non-Hodgkin (drug therapy) Lymphoma, Large B-Cell, Diffuse (drug therapy, pathology) Antibodies, Bispecific (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!